{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:18:29Z","timestamp":1792595909996,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115893","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T15:02:02Z","timestamp":1698073322000},"page":"115893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors"],"prefix":"10.1016","volume":"262","author":[{"given":"Jiayuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhewen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1581-6155","authenticated-orcid":false,"given":"Yechun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115893_bib1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115893_bib2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115893_bib3","doi-asserted-by":"crossref","first-page":"L332","DOI":"10.1152\/ajplung.00384.2003","article-title":"Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers","volume":"287","author":"Barber","year":"2004","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejmech.2023.115893_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ejcb.2006.01.006","article-title":"Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells","volume":"85","author":"Millen","year":"2006","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115893_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/leu.2015.302","article-title":"A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma","volume":"30","author":"Suhasini","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2023.115893_bib6","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/01.RES.0000261934.56938.38","article-title":"cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling","volume":"100","author":"Houslay","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2023.115893_bib7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","article-title":"Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages","volume":"76","author":"Maier","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2023.115893_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101342","article-title":"Inhibition of PDE4 protects neurons against oxygen-glucose deprivation-induced endoplasmic reticulum stress through activation of the Nrf-2\/HO-1 pathway","volume":"28","author":"Xu","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejmech.2023.115893_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmech.2019.02.026","article-title":"Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect","volume":"168","author":"Tang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115893_bib10","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41467-021-21713-3","article-title":"Pharmacological rescue in patient iPSC and mouse models with a rare DISC1 mutation","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115893_bib11","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ijnp\/pyaa048","article-title":"The Phosphodiesterase-4 inhibitor roflumilast, a potential treatment for the comorbidity of memory loss and depression in Alzheimer\u2019s disease: a preclinical study in APP\/PS1 transgenic mice","volume":"23","author":"Wang","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2023.115893_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154125","article-title":"\u03b1-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson\u2019s disease models through PKA activation","volume":"101","author":"Chen","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2023.115893_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(05)17708-3","article-title":"Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease","volume":"365","author":"Lipworth","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115893_bib14","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/bph.14667","article-title":"Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity","volume":"176","author":"Li","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115893_bib15","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1021\/acs.jmedchem.9b00518","article-title":"Structure-Aided identification and optimization of tetrahydro-isoquinolines as novel PDE4 inhibitors leading to discovery of an effective antipsoriasis agent","volume":"62","author":"Zhang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115893_bib16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrd3276","volume":"9","author":"Fabbri","year":"2010","journal-title":"Roflumilast, Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115893_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115893_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1358\/dot.2017.53.4.2604174","article-title":"Crisaborole: phosphodiesterase inhibitor for treatment of atopic dermatitis","volume":"53","author":"Paton","year":"2017","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejmech.2023.115893_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.coph.2005.04.001","article-title":"Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors","volume":"5","author":"Giembycz","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115893_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.ijir.3900802","article-title":"Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters","volume":"14","author":"Lin","year":"2002","journal-title":"Int. J. Impot. Res."},{"key":"10.1016\/j.ejmech.2023.115893_bib21","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1074\/jbc.M106562200","article-title":"Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells","volume":"277","author":"Rybalkin","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115893_bib22","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1111\/jth.15844","article-title":"The NO\/cGMP\/PKG pathway in platelets: the therapeutic potential of PDE5 inhibitors in platelet disorders","volume":"20","author":"Degjoni","year":"2022","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2023.115893_bib23","article-title":"Phosphodiesterase 5 inhibitors for pulmonary hypertension","volume":"1","author":"Barnes","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2023.115893_bib24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.tem.2011.05.004","article-title":"Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism?","volume":"22","author":"Armani","year":"2011","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2023.115893_bib25","doi-asserted-by":"crossref","first-page":"H1398","DOI":"10.1152\/ajpheart.ajpheart.91438.2007","article-title":"Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice","volume":"294","author":"Salloum","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejmech.2023.115893_bib26","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/CIRCULATIONAHA.111.065300","article-title":"Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity","volume":"125","author":"Kim","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2023.115893_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10557-014-6559-0","article-title":"Tadalafil prevents acute heart failure with reduced ejection fraction in mice","volume":"28","author":"Salloum","year":"2014","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejmech.2023.115893_bib28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41419-017-0202-5","article-title":"PDE5 inhibition eliminates cancer stem cells via induction of PKA signaling","volume":"9","author":"Klutzny","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2023.115893_bib29","doi-asserted-by":"crossref","first-page":"H1558","DOI":"10.1152\/ajpheart.00865.2013","article-title":"Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO\/SIRT1\/PGC-1\u03b1 signaling","volume":"306","author":"Koka","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejmech.2023.115893_bib30","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1212\/WNL.0000000000000498","article-title":"PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy","volume":"82","author":"Nelson","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2023.115893_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/npp.2016.163","article-title":"A First-in-Class small-molecule that acts as a dual inhibitor of HDAC and PDE5 and that rescues hippocampal synaptic impairment in Alzheimer's disease mice","volume":"42","author":"Cuadrado-Tejedor","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2023.115893_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","article-title":"Drug repurposing for rare diseases","volume":"42","author":"Roessler","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115893_bib33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115893_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115893_bib35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1124\/jpet.114.220541","article-title":"CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration","volume":"352","author":"Moretto","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115893_bib36","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/s41386-018-0178-6","article-title":"Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice","volume":"43","author":"Zhang","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2023.115893_bib37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/archotol.1981.00790400029006","article-title":"Effect of ethaverine hydrochloride on cochlear microcirculation","volume":"107","author":"Prazma","year":"1981","journal-title":"Arch. Otolaryngol."},{"key":"10.1016\/j.ejmech.2023.115893_bib38","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/00007611-197512000-00007","article-title":"Pharmacology of ethaverine HC1: human and animal studies","volume":"68","author":"Oswald","year":"1975","journal-title":"South. Med. J."},{"key":"10.1016\/j.ejmech.2023.115893_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/jama.1953.02940180014004","article-title":"Ethaverine in the treatment of angina pectoris","volume":"153","author":"Voyles","year":"1953","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejmech.2023.115893_bib40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/000331978603700502","article-title":"Effects of ethaverine hydrochloride on the walking tolerance of patients with intermittent claudication","volume":"37","author":"Trainor","year":"1986","journal-title":"Angiology"},{"key":"10.1016\/j.ejmech.2023.115893_bib41","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1248\/bpb.24.838","article-title":"Inhibitory effects of ethaverine, a homologue of papaverine, on monoamine oxidase activity in mouse brain","volume":"24","author":"Lee","year":"2001","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2023.115893_bib42","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.str.2004.10.004","article-title":"Structural basis for the activity of drugs that inhibit phosphodiesterases","volume":"12","author":"Card","year":"2004","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2023.115893_bib43","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115893_bib44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s42358-019-0080-x","article-title":"Benzbromarone in the treatment of gout","volume":"59","author":"Azevedo","year":"2019","journal-title":"Adv. Rheumatol."},{"key":"10.1016\/j.ejmech.2023.115893_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7635274","article-title":"Benzbromarone attenuates oxidative stress in angiotensin II- and salt-induced hypertensive model rats","volume":"2018","author":"Muraya","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejmech.2023.115893_bib46","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/ATVBAHA.117.309128","article-title":"Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-\u03baB signaling pathway in HepG2 cells","volume":"37","author":"Spiga","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2023.115893_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117272","article-title":"Benzbromarone mitigates cisplatin nephrotoxicity involving enhanced peroxisome proliferator-activated receptor-alpha (PPAR-\u03b1) expression","volume":"243","author":"Abdel-Razek","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2023.115893_bib48","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1038\/s41467-022-32674-6","article-title":"CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis","volume":"13","author":"Guo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115893_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.034","article-title":"The Global phosphorylation landscape of SARS-CoV-2 infection","volume":"182","author":"Bouhaddou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115893_bib50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.it.2017.12.002","article-title":"Protein kinase CK2: an emerging regulator of immunity","volume":"39","author":"Gibson","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejmech.2023.115893_bib51","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s12272-013-0103-9","article-title":"Pharmacokinetic characterization of CK2 inhibitor CX-4945","volume":"36","author":"Son","year":"2013","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.ejmech.2023.115893_bib52","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","article-title":"CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy","volume":"70","author":"Siddiqui-Jain","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115893_bib53","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.312","article-title":"Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: a phase Ib\/II study","volume":"39","author":"Borad","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115893_bib54","author":"Senhwa"},{"key":"10.1016\/j.ejmech.2023.115893_bib55","doi-asserted-by":"crossref","first-page":"29207","DOI":"10.1074\/jbc.272.46.29207","article-title":"CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation","volume":"272","author":"Brooks","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115893_bib56","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/92.5.376","article-title":"Preclinical and clinical development of cyclin-dependent kinase modulators","volume":"92","author":"Senderowicz","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2023.115893_bib57","doi-asserted-by":"crossref","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2023.115893_bib58","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1021\/jm5002315","article-title":"Thermodynamic and structural characterization of halogen bonding in protein-ligand interactions: a case study of PDE5 and its inhibitors","volume":"57","author":"Ren","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115893_bib59","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1021\/acs.jmedchem.9b00123","article-title":"Pharmacokinetics-driven optimization of 4(3 H)-pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115893_bib60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s41365-018-0398-9","article-title":"Upgrade of macromolecular crystallography beamline BL17U1 at SSRF","volume":"29","author":"Wang","year":"2018","journal-title":"Nucl. Sci. Tech."},{"key":"10.1016\/j.ejmech.2023.115893_bib61","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1107\/S0907444906019949","article-title":"HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes","volume":"62","author":"Minor","year":"2006","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2023.115893_bib62","article-title":"Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment","volume":"211","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115893_bib63","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1107\/S0907444994003112","article-title":"The ccp4 suite - programs for protein crystallography","volume":"50","author":"Bailey","year":"1994","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2023.115893_bib64","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2023.115893_bib65","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1107\/S0907444902016657","article-title":"PHENIX: building new software for automated crystallographic structure determination","volume":"58","author":"Adams","year":"2002","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2023.115893_bib66","series-title":"AMBER 2018","author":"Case","year":"2018"},{"key":"10.1016\/j.ejmech.2023.115893_bib67","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2023.115893_bib68","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2023.115893_bib69","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2023.115893_bib70","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1021\/j100142a004","article-title":"A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model","volume":"97","author":"Bayly","year":"1993","journal-title":"J. Phys. Chem."},{"key":"10.1016\/j.ejmech.2023.115893_bib71","series-title":"Gaussian 09, Revision A.02","author":"Frisch","year":"2016"},{"key":"10.1016\/j.ejmech.2023.115893_bib72","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"key":"10.1016\/j.ejmech.2023.115893_bib73","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N\u22c5 log (N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ejmech.2023.115893_bib74","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA. py: an efficient program for end-state free energy calculations","volume":"8","author":"Miller","year":"2012","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2023.115893_bib75","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1021\/jacs.6b02682","article-title":"Interaction entropy: a new paradigm for highly efficient and reliable computation of protein-ligand binding free energy","volume":"138","author":"Duan","year":"2016","journal-title":"J. Am. Chem. Soc."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:59:42Z","timestamp":1759330782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423008607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":75,"alternative-id":["S0223523423008607"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115893","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115893"}}